Skip to main content
RemeGen Co., Ltd. logo

RemeGen Co., Ltd. — Investor Relations & Filings

Ticker · 9995 ISIN · CNE1000048G6 LEI · 300300M9HCX4TFAD4I10 HKEX Manufacturing
Open in API
Filings indexed 1,624 across all filing types
Latest filing 2022-12-12 Regulatory Filings
Country CN China
Listing HKEX 9995

About RemeGen Co., Ltd.

http://www.remegen.com

RemeGen Co., Ltd. is a biopharmaceutical company dedicated to the discovery, development, production, and commercialization of innovative biological drugs. The company focuses on creating first-in-class and best-in-class therapeutics to address significant unmet clinical needs, particularly in the critical therapeutic areas of autoimmune diseases, oncology, and ophthalmology. RemeGen utilizes proprietary technology platforms capable of discovering, screening, and developing new molecules and efficiently optimizing production processes. Its pipeline includes a series of innovative biologics, such as Telitacicept, and features 8 clinical pipelines, over 40 clinical trials, and more than 600 patent applications, demonstrating a strong commitment to R&D and innovation in biopharmaceuticals.

Recent filings

Filing Released Lang Actions
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2022-12-12 English
Notification Letter and Request Form to Non-Registered Holders-Notice of Publication of Extraordinary General Meeting Circular ("Current Corporate Communications")
Report Publication Announcement Classification · 95% confidence The document is a notification letter from RemeGen Co., Ltd. addressed to non-registered shareholders regarding the publication of an Extraordinary General Meeting (EGM) circular. It provides information on how shareholders can access the circular electronically or request a printed version. The document includes a request form for shareholders to indicate their preference for receiving corporate communications. There is no actual financial data, detailed report content, or financial statements included. The document is essentially an announcement about the availability of a corporate communication (the EGM circular) rather than the circular itself or any other report. Therefore, it fits the definition of a Report Publication Announcement (RPA). The document length (6807 characters) and content support this classification as it is not a full report but a notification about the report's publication and access.
2022-12-09 English
PROXY FORM FOR USE AT THE 2022 FIRST CLASS MEETING OF H SHAREHOLDERS
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a proxy form for use at a shareholders' meeting, specifically the 2022 first class meeting of H shareholders of RemeGen Co., Ltd. It contains instructions for appointing a proxy to vote on resolutions related to the 2022 Restricted A Share Incentive Scheme. The content is procedural and related to voting at a shareholder meeting, not a report or announcement of financial results or corporate changes. This type of document is used to solicit votes and provide information to shareholders for decision-making at a meeting, which fits the definition of Proxy Solicitation & Information Statement (PSI). The document length is 6876 characters, which is consistent with a detailed proxy form rather than a brief announcement or a full report. Therefore, the correct classification is PSI.
2022-12-09 English
NOTICE OF 2022 FIRST CLASS MEETING OF H SHAREHOLDERS
Regulatory Filings Classification · 95% confidence The document is a notice of a shareholders' meeting (Class Meeting of H Shareholders) for RemeGen Co., Ltd. It includes details about the meeting date, location, agenda items (approval of a restricted share incentive scheme), proxy voting instructions, and shareholder eligibility. There is no financial data, earnings information, or detailed report content. The document is an announcement of a meeting and the resolutions to be considered, not a report or results announcement. It is not a proxy solicitation or voting results announcement, as it precedes the meeting and does not provide voting outcomes. The document fits best as a Regulatory Filing (RNS) because it is a formal regulatory announcement related to corporate governance and shareholder meetings but does not fall into more specific categories like AGM Information or Proxy Solicitation. The length and content confirm it is not a brief announcement or a report publication notice.
2022-12-09 English
PROXY FORM FOR USE AT THE 2022 SECOND EXTRAORDINARY GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a proxy form for the 2022 second extraordinary general meeting of RemeGen Co., Ltd. It includes instructions for appointing a proxy to vote on resolutions related to the 2022 Restricted A Share Incentive Scheme. The content is procedural and related to voting at a shareholder meeting, not a report or announcement of financial results or management changes. It is not a report itself but a solicitation of votes for the meeting. This fits the definition of Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2022-12-09 English
NOTICE OF 2022 SECOND EXTRAORDINARY GENERAL MEETING
Regulatory Filings Classification · 95% confidence The document is a notice for the 2022 second extraordinary general meeting (EGM) of RemeGen Co., Ltd. It includes details about the meeting date, location, agenda items (special resolutions related to a restricted share incentive scheme), proxy voting instructions, and other procedural notes. There are no financial statements, audit information, or detailed management discussion. The document is clearly an announcement of a shareholder meeting rather than a report or transcript. It fits the category of a meeting notice, which aligns with the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or Proxy Solicitation & Information Statement (PSI). However, since this is a notice of the meeting itself and not the voting results or proxy solicitation materials, it is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about the meeting. The document length is about 5079 characters, which is not extremely short, but the content is purely a meeting notice without results or proxy materials. Therefore, the best fit is Regulatory Filings (RNS).
2022-12-09 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.